What question did this study set out to answer?

The aim is to evaluate the acute efficacy and safety of cannabinol for treating insomnia disorder.

Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the acute efficacy and safety of cannabinol for treating insomnia disorder.
Randomized, double-blind, placebo-controlled, three-arm, single-night crossover design.
Twenty adults with diagnosed insomnia participated and received either 30 mg or 300 mg of cannabinol or placebo.
Sleep metrics were measured using polysomnography, focusing on wake after sleep onset.
Cannabinol did not significantly change wake after sleep onset for either dosage.
The 300 mg dose increased non-rapid eye movement-2 sleep.
Subjective sleep quality improved with 300 mg, alongside reduced sleep onset latency and electroencephalographic arousal indices.

No takes yet. Share an insight, caveat, or question.

Randomized trial investigates cannabinol's impact on insomnia disorder, suggesting potential benefits for sleep quality.

Lavender et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark